IMRX Stock Analysis: Buy, Sell, or Hold?
IMRX - Immuneering Corporation Class A Common Stock
$5.45
0.12 (2.25%)
▲
5d:
+4.41%
30d:
+5.42%
90d:
-17.17%
BUY
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 04, 2026
28d
Smart Money Accumulation
IMRX is down 11.7% this week, but smart money is accumulating calls. Top strike: $5 2026-05-15 with 360 OI. Call ratio: 61% View Scanner →
Strength: 7.0/10
Get Alerted When IMRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: IMRX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: IMRX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: IMRX is currently trading at $5.45, which is considered extended relative to its 30-day fair value range of $4.91 to $5.40.
Technical Outlook: Technically, IMRX is in a strong uptrend. The price is approaching resistance at $5.59. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: IMRX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $17.00 (+211.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IMRX is in a strong uptrend. The price is approaching resistance at $5.59. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: IMRX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $17.00 (+211.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$4.91 -
$5.40
Company Quality Score
66/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
70.8%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 211.9% below Wall St target ($17.00)
Fair Price Analysis
30-Day Fair Range
$4.91 -
$5.40
Current vs Fair Value
EXTENDED
Expected Move (7 Days)
±$0.70
(12.9%)
Support & Resistance Levels
Support Level
$4.76
Resistance Level
$5.59
Current Trend
Strong Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.03
Wall Street Target
$17.00
(+211.9%)
Revenue Growth (YoY)
-99.8%
Share & Embed Analysis
Last updated: April 05, 2026 8:47 AM ET
Data refreshes hourly during market hours. Next update: 9:47 AM
Data refreshes hourly during market hours. Next update: 9:47 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IMRX showing a specific setup today?
Insider Activity (6 Months)
5
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Harold Eugene Brakewood
BUY
5250 shares
2026-01-16
Brett Matthew Hall
BUY
2298 shares
2026-01-15
Thomas J Schall
BUY
21645 shares
2026-01-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 56 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1018 | 56 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$132 | 58 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 60 HOLD |
